228 related articles for article (PubMed ID: 32574418)
1. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.
Sharma P; Moore K; Ganger D; Grewal P; Brown RS
Liver Transpl; 2020 Oct; 26(10):1328-1336. PubMed ID: 32574418
[TBL] [Abstract][Full Text] [Related]
2. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
[TBL] [Abstract][Full Text] [Related]
5. A study on clinical outcomes of combination of terlipressin and albumin in Hepatorenal Syndrome.
Krishna R; Raj J; Dev D; Prasad SC; Reghu R; V SO
Scand J Gastroenterol; 2020 Jul; 55(7):860-864. PubMed ID: 32634332
[TBL] [Abstract][Full Text] [Related]
6. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
[TBL] [Abstract][Full Text] [Related]
7. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
Weinberg EM; Wong F; Vargas HE; Curry MP; Jamil K; Pappas SC; Sharma P; Reddy KR
Liver Transpl; 2024 Apr; 30(4):347-355. PubMed ID: 37801553
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
9. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
[TBL] [Abstract][Full Text] [Related]
10. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Duong N; Kakadiya P; Bajaj JS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
[TBL] [Abstract][Full Text] [Related]
11. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.
Zhang J; Rössle M; Zhou X; Deng J; Liu L; Qi X
Curr Med Res Opin; 2019 May; 35(5):859-868. PubMed ID: 30474439
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Nanda A; Reddy R; Safraz H; Salameh H; Singal AK
J Clin Gastroenterol; 2018 Apr; 52(4):360-367. PubMed ID: 28991106
[TBL] [Abstract][Full Text] [Related]
14. Hepatorenal syndrome.
Angeli P; Morando F; Cavallin M; Piano S
Contrib Nephrol; 2011; 174():46-55. PubMed ID: 21921608
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Kulkarni AV; Lee J; Reddy KR
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
[TBL] [Abstract][Full Text] [Related]
17. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
Boyer TD; Sanyal AJ; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Gülberg V; Sigal S; Bexon AS; Teuber P;
Liver Transpl; 2011 Nov; 17(11):1328-32. PubMed ID: 21837734
[TBL] [Abstract][Full Text] [Related]
18. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
20. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
Erstad BL
Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]